SEOUL, KOREA - The shares of Chong Kun Dang Pharmaceutical Corp. were traded at 77,000 won at 9:08 am on March 10, up 1.58 percent from the previous trading day's 75,800 won. Tongyang Securities analyst Kim Mi-hyun said in a report on the same day the drug maker would make a two-digit growth in both sales revenue and operating profit following last year.

 

For example, its Tamiflu, the antiviral drug known to prevent or slow the spread of flu virus, was in short supply this winter due to high incidence of influenza. Chong Kun Dang holds a monopoly position in the supply of Tamiflu in Korea. The company estimated its Tamiflu sales this year would be in the range of 20 billion won, about triple that of the 2012 and 2013 average of 6.6 billion won.

 

The company expected its sales revenue and operating profit for the year would be 560 billion won and 73 billion won, respectively, up 10 percent and 16 percent from the previous year.